NVST:NYSEEnvista Holdings Corporation Analysis
Data as of 2026-08-01 - not real-time
$27.31
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Envista Holdings (NVST) is trading at $27.31, just above its 20‑day SMA (26.72) and comfortably above the 50‑day SMA (25.48), with a bullish MACD crossover and an RSI of 56 indicating modest upside momentum. Technicals point to a bullish trend, while the DCF‑derived fair value of $27.87 suggests roughly 8% upside, aligning with analyst median targets near $30.
Fundamentally, revenue is growing at 14% YoY and margins are solid (gross 55%, operating 10%), but profit margins remain thin (2.4%). Forward EPS of $1.57 versus trailing $0.41 drives the forward P/E down to 17x, a stark improvement over the trailing 66x, though the stock remains expensive relative to the industry average P/E of 29x. The balance sheet shows $1.08B cash offsetting $1.59B debt, leaving modest net leverage, and the company pays no dividend.
Fundamentally, revenue is growing at 14% YoY and margins are solid (gross 55%, operating 10%), but profit margins remain thin (2.4%). Forward EPS of $1.57 versus trailing $0.41 drives the forward P/E down to 17x, a stark improvement over the trailing 66x, though the stock remains expensive relative to the industry average P/E of 29x. The balance sheet shows $1.08B cash offsetting $1.59B debt, leaving modest net leverage, and the company pays no dividend.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above short‑term moving averages
- DCF upside of ~8% and analyst price targets above current level
- Upcoming Q2 earnings release could confirm earnings acceleration
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward earnings growth reflected in a forward P/E of 17x
- Improving operating margins and stable cash flow generation
- Consensus analyst recommendation of "Buy" with 14 analysts covering the stock
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Moderate leverage and solid cash position support financial stability
- Exposure to regulatory changes in dental device approvals
- High beta (≈1.3) and 30‑day volatility (~34%) suggest price swings that merit a cautious stance
Key Metrics & Analysis
Financial Health
Revenue Growth14.40%
Profit Margin2.41%
P/E Ratio66.6
ROE2.21%
ROA3.01%
Debt/Equity51.61
P/B Ratio1.4
Op. Cash Flow$272.1M
Free Cash Flow$216.3M
Industry P/E29.2
Technical Analysis
TrendBullish
RSI56.7
Support$25.22
Resistance$28.84
MA 20$26.72
MA 50$25.48
MA 200$24.33
MACDBullish
VolumeStable
Fear & Greed Index92.88
Valuation
Fair Value$27.87
Target Price$29.43
Upside/Downside7.76%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.30
Volatility34.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
1157
Zoomlion Heavy Industry Science and Technology Co., Ltd.
STOCK600835
Shanghai Mechanical & Electrical Industry Co., Ltd. Class A
STOCK002648
Satellite Chemical Co. Ltd. Class A
STOCK600426
Shandong Hualu-Hengsheng Chemical Co., Ltd. Class A
STOCK603501
OmniVision Integrated Circuits Group, Inc. Class A
STOCK600309
Wanhua Chemical Group Co. Ltd. Class A
STOCKThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.